INTRODUCTION

Infectious hematopoietic necrosis virus (IHNV) is the most important viral pathogen of salmonids in North
America. Originally enzootic on the west coast of North America, IHNV has been detected in other areas of the world where salmonid fishes are found. Significant economic impacts by IHNV on public and private aquaculture have motivated researchers to work towards the development of a safe and effective vaccine. DNA vaccines have successfully been used to protect 'Corresponding author. E-mail: gael-kurath@usgs.gov many species against various pathogens. In salmon and trout, the glycoprotein genes of pathogenic rhabdoviruses, including IHNV and viral haemorragic septicemia virus (VHSV) (Anderson et al. 199613, Boudinot et al. 1998 , Lorenzen et al. 1998 , have been shown to be protective when used in a DNA vaccine. Other gene products, however, have been given little attention because most vaccines aim at presenting surface proteins to the host immune system. It is known that cytotoxic T-lymphocytes (CTL) in both mice and humans play an important role in the immune response by recognizing epitopes derived from conserved internal virion proteins (Paul 1999) . The role of IHN viral proteins as inducers of CTL activity is unknown. A vaccine Dis Aquat Org 39: [29] [30] [31] [32] [33] [34] [35] [36] 1999 able to stimulate CTLs in fish may confer protection against different strains of IHNV and would be a useful tool in the study of viruses and their interaction with the fish immune system.
Recent studies have shown that DNA vaccines containing internal viral proteins such as the core protein of lymphocytic choriomeningitis virus (Yokoyama et al. 1995) , or the nucleoprotein of either the measle virus (Fooks et al. 1996) or the influenza virus (Ulmer et al. 1993) , are capable of stimulating both humoral and T-cell responses in mice. Furthermore, Lorenzen et al. (1998) demonstrated in rainbow trout that a DNA vaccine containing only the nucleocapsid (N) gene of VHSV was able to induce some level of protective immunity against viral challenge. In contrast, a DNA vaccine encoding the N gene of IHNV was shown not to induce antibody response or protection in rainbow trout against viral challenge (Anderson et al. 1996b ). This inconsistency between these studies prompted us to re-test, with new vaccine constructs, the ability of individual viral proteins to protect rainbow trout against an immersion challenge with IHNV.
The objective of this study was to evaluate the immunogenicity of the nucleocapsid protein (N), phosphoprotein (P), matrix protein (M) and non-virion protein (NV) in comparison to the glycoprotein (G) of IHNV in rainbow trout Oncorhynchus mykiss. DNA vaccines were produced by inserting the genes coding for the various viral proteins in the plasmid pCDNA 3.1 (Invitrogen, Carlsbad, CA). The protective immunity of each vaccine was evaluated by measuring the survival of immunized fry after challenge with live virus. Neutralizing antibody titers were also determined and the passive immunization of na'ive fry was performed to further assess potential protective mechanisms.
MATERIALS AND METHODS
Virus and cell culture. An epithelioma papulosum cyprini (EPC) cell line (Fijan et al. 1983 ) and chinook salmon embryo (CHSE-214) cell line (Lannan et al. 1984) were used for the propagation of IHNV. Cells were maintained at 15 to 17OC in minimum essential medium (MEM) (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (Hyclone, Logan, Utah) and 2 mM L-glutamine (GIBCO, Grand Island, NY). IHNV isolate 220-90 (LaPatra et al. 1991a ) was used to infect cells at a multiplicity of infection of 0.1 and incubated at 15 to 17°C. Quantification of virus used in fish challenge or isolated from dead fish was performed by plaque assay procedures previously described (LaPatra et al. 1989) .
DNA plasmid constructs. The open reading frames of the N, P, M, NV and G genes of IHNV isolate 039-82 (the WRAC strain) were amplified by reverse transcriptase-polymerase chain reaction using sequence specific primers (Morzunov et al. 1995 ) (IHNV isolate 039-82 genbank accession number L40883) and cloned into the pT7-blue vector (Novagen, Madison, WI). The genes were then subcloned downstream of the immediate-early enhancer-promoter sequences of human cytomegalovirus (CMV) of the pCDNA 3.1 vector (Invitrogen). The resulting plasmids, designated pCDNA-N, pCDNA-P, pCDNA-M, pCDNA-NV and pCDNA-G, contained the IHNV N, P, M, NV, and G genes respectively. The P-galactosidase construct (pCDNA-P-gal) was made by subcloning the P-galactosidase gene from the pCMVP-gal vector (Anderson et al. 1996a) into pCDNA 3.1. All constructs were multiplied in Escherichia coli strain DH5a cells grown in Luria broth media, and plasmid DNA was purified with anionexchange chromatography columns (Quiagen, Chastworth, CA). The N, P, M, NV, G and P-galactosidase (P-gal) inserts in the constructs were sequenced at their 5' and 3' ends in order to insure the correct onentation and reading frame of the genes.
Confirmation of protein synthesis. The capacity of the plasmids to express the G, N and P-gal proteins in vitro was assessed in transfected EPC cells. Two milliliters of EPC cells (1 X 106 cells ml-') were plated onto larninin coated microscope glass slides (Sigma) and incubated in a 100 mm diameter petri-dish for 1 h at room temperature followed by the addition of 5 m1 of Opti-MEM medium (GIBCO). The slides were then incubated overnight at 25OC and transfected with 2 pg of the appropriate DNA plasmid in lipofectamine prepared according to the manufacturer's protocol (GIBCO). The DNA-lipid complex was incubated with the cells for 24 h. Following transfection, the DNA lipid complex was rinsed from the cells with RPMI-1640 medium (GIBCO) containing no fetal bovine serum or antibiotics. The cells were incubated in a sealed plastic container filled with a gas mixture containing 10% mol/mol carbon dioxide, 10% mol/mol oxygen and 80% nitrogen (Airgas, Portland, OR) . Approximately 48 h after transfection, cells were rinsed with phosphate buffered saline (PBS; pH 7.4) and fixed in cold acetone for 5 min (G and N) or 1 % glutaraldehyde for 20 min (P-galactosidase). The expression of the G and N genes was confirmed by indirect immunofluorescence while the 0-galactosidase activity was assessed by incubating transfected cells with X-gal solution (0.2% X-gal chromagen, 10 mM sodium phosphate, 150 mM NaC1, 1 mM MgC12, 3.3 mM K,Fe(CN)6.3H20, and 3.3 mM K,Fe(CN)6, pH 7.0) at 37°C for 16 h.
Indirect immunofluorescence. Transfected cells were incubated for 60 min in a mixture of 3 mouse monoclonal antibodies (rnAbs) (1H8, 5A6 and 6A7) directed against the G protein of IHNV isolate 039-82 (Huang et al. 1996) or the mAb 1NDW14D directed against the IHNV N protein (Ristow et al. 1993) . Cells were rinsed with PBS and reacted with an anti-mouse IgG goat fluorescein isothiocyanate labeled antibody (Sigma) for 60 min. Cells were then rinsed with PBS and stained for 1 min with a 0.05% solution Evans blue.
After addition of glycerol and a coverslip, cells were viewed under an epifluorescence microscope using a BP 450-490 nm filter.
Vaccination and bleeding of larger fish. Sockeye salmon Oncorhynchus nerka (mean weight 150 g) were injected with 25 1-19 of DNA in 200 p1 Tris-EDTA buffer and held in 369 1 aquaria at a temperature of 12°C. Six weeks after vaccination, the fish were bled, sera were collected and neutralizing antibody titers were determined as previously described .
Passive immunization and challenge of rainbow trout fry. Rainbow trout (mean weight, 1 g) were anaesthetized by immersion in a 100 pg ml-' concentration of tricaine methane sulfonate (MS-222; Argent Chemical Laboratories, Redmond, WA) and were injected intraperitoneally with 50 p1 of pooled sera obtained from vaccinated sockeye salmon or with sterile PBS. Each treatment group was placed in a separate aquarium receiving ultraviolet-disinfected, single-pass spring water at a constant temperature (15°C) for 24 h. Duplicate groups of fish from each treatment were challenged with IHNV (isolate 220-90; LaPatra et al. 1991b) (105 PFU ml-l) in an amount of water equalling 10 times the total weight of the fish, for 1 h in closed systems with aeration. Each group was then placed in a separate 19 1 aquarium and monitored for 21 d for mortality.
Vaccination, challenge and bleeding of rainbow trout fry. Rainbow trout (mean weight 2 g) were anaesthetized as described above and injected intramuscularly at the base of the dorsal fin with 1, 5 or 10 pg of the appropriate DNA vaccine in 25 p1 Tris-EDTA buffer. Each treament group was placed in separate 19 to 32 1 aquaria at a temperature of 12°C. Three to 6 wk post-immunization, groups of 20 to 25 fish (in duplicate) representing each treatment were challenged by immersion in water containing 105 PFU ml-' of IHNV isolate 220-90 by standard procedures (LaPatra et al. 1991b ). Fourteen and 16 g fish from the duration of protection experiment were challenged by intraperitoneal injection of 100 p1 solution of 106 PFU ml-' of IHNV isolate 220-90 at 58 and 80 d post-vaccination respectively. Average cumulative percent mortality was calculated for each experimental group. Experimental groups were held in separate 19 1 aquaria at a temperature of 15"C, monitored 21 to 28 d for mortality, and fed a d libitum a dry pelleted diet (Clear Spring Foods, Inc.) daily. At least 20% of the fish that died on any given day were tested for virus. Rainbow trout fry used for the duration of protection experiment were bled in pools of 3 to 5 fish at Day 80 and in pools of 4 to 6 fish at Day 102 post-vaccination and their neutralizing antibody titers were determined.
RESULTS
Expression of the IHNV proteins and control proteins in transfected cells
Expression of the IHNV N and G proteins by plasmids pCDNA-N and pCDNA-G, respectively, was confirmed by immunohistochemical staining of EPC cells transfected with the DNA plasmids (Fig. 1) . The pCDNA-N and pCDNA-G transfected cells reacted with the appropriate N or G specific antibodies. Similarly, cells transfected with pCDNA-P-gal were shown to express the P-galactosidase control protein (results not shown). Since the IHNV P, M and NV genes were cloned into the same vector using identical methods, we assume the plasmids pCDNA-P, pCDNA-M and pCDNA-NV were also competent to express these proteins, although this could not be confirmed due to the lack of monoclonal antibody reagents specific for these proteins, and the high background obtained in immunohistochemical staining with polyclonal IHNV antiserum (data not shown).
Protection of fry from virus challenge 4 to 6 wk post-vaccination Rainbow trout fry immunized with each vaccine construct were tested for protection against an IHNV immersion challenge at 4 to 6 wk post-immunization. In 3 consecutive experiments, rainbow trout fry immunized with 10, 5 or 1 pg of pCDNA-G exhibited significantly (p < 0.01) less mortality than fry vaccinated with the vector alone or with pCDNA-p-gal. Cumulative percent mortality in fish immunized with pCDNA-G ranged from 0 to 2% whereas mortality in fish immunized with DNA vaccines that contained other proteins or were left unhandled ranged from 36 to 76 % (Table 1) . There was no significant Wference in mortality or mean day to death for fish immunized with pCDNA-N, pCDNA-M, pCDNA-P or pCDNA-NV relative to control vaccine groups. No mortality occurred in any of the mock infected control groups for each treatment that were not exposed to virus. At least 20 % of the immunized fish from all groups that died following exposure to IHNV were tested for presence of IHNV in liver-kidney-spleen samples. In the 3 experiments virus was recovered from 94 to 98% (134/140) Rainbow trout fry immunized with 1 pg of either pCDNA-N or pCDNA-NV vaccines showed curnulative percent mortality ranging from 67 to l00 % when challenged with IHNV at 28, 58 and 80 d post-immunization (Table 2) . No significant difference in mortality was seen between pCDNA-N and pCDNA-NV groups compared with the pCDNA-P-gal vaccinated group of fry, which showed 60 to 98 % cumulative mortality for the same time points (Table 2 ). In addition, pCDNA-G immunized fry exhibited a cumulative percent mortality of 2, 31, and 49 % when challenged with IHNV at 28, 58 and 80 d, respectively, post-immunization. Statistical analysis showed significant difference in mortality between the pCDNA-G group (p < 0.01) and the pCDNA-P-gal group at all time points (Table 2) . Among rainbow trout challenged with IHNV, virus was recovered from 95% (157/165) of the fish that were examined. The mean IHNV concentration was 106.87 PFU g-I (range to >107.3 PFU g-l) in combined liver-spleen-kidney samples.
At 80 and 102 d post-immunization, (Table 3) . Neutralizing antibody titers were also determined from groups of pCDNA-G Virus neutralizing antibody activity in 150 g sockeye salmon Sockeye salmon vaccinated with 25 pg of pCDNA-G had IHNV neutralization titers ranging from 80 to 320 at 6 wk post-vaccination, indicating that these 5 fish responded specifically to IHNV. None of the 5 fish vaccinated with pCDNA-M or the 4 control fish vaccinated with pCDNA-P-gal exhibited detectable neutralization titers (Table 4) .
Protection provided by pooled sera after passive immunization
Rainbow trout fry were passively immunized with sera obtained from 150 g sockeye salmon that had been previously immunized with pCDNA-G or pCDNA-P-gal. Control fry were injected with buffer. "Antibody t~t e r s are reported as the rec~procal of the h~g hest d~l u t~o n that resulted In a 50% reduct~on In the avera g e number of plaques detected In the n e g a t~v e control wells Table 4 Oncorhyncl~us nerka Ant1 IHNV neutralizing antirainbow trout fry with relatlve surv~val ranglng from body ttters detected in l n d~v~d u a l adult sockeye salmon vac-97 to 100 % ~h~~ the previous report of pro.
cinated w~t h plasmld DNA tection induced by an IHNV G DNA vacclne in rainbow trout fry (Anderson et a1 199613) The other vlral proteins of IHNV (N, P, M and NV) that were tested did not induce any significant level of protection in fry since the mean cumulative mortality of fish immunized with the pCDNA-M, pCDNA-P, pCDNA-N and pCDNA-NV vaccines did not differ statistically from the pCDNA-P-gal or vector alone negative control vaccines These results suggest that no specific or nonspecific lmmune response was induced by these viral Following immersion challenge with IHNV, fry immunized with pCDNA-G and pCDNA-P-gal had relative survivals of 100 and 58%, respectively, compared to control fry (Table 5) . No mortality was recorded in the non-infected fry control groups. Among rainbow trout challenged with IHNV, virus was recovered from 97 O/o (37/38) of the fish that were examined. The mean IHNV concentration was 10" PFU g-' (range 102' to PFU g-l) in combined liver-spleenkidney samples.
DISCUSSION
The goal of this study was to evaluate the protective immunogenicity of individual IHNV proteins expressed by DNA vaccines. In the first set of experiments, the pCDNA-G vaccine induced significant protection in vaccines.
Although only the G protein of IHNV is known to elicit a neutralizing antibody response in fish (Engelking & Leong 1989), we anticipated some level of protection from vaccination using other viral proteins, possibly as a result of the induction of other immune mechanisms. For instance, Oberg et al. (1991) showed an augmentation in the efficacy of a recombinant fusion G subunit protein vaccine against IHNV by addition of the N-fusion protein to the vaccine preparation. Furthermore, a study by Lorenzen et al. (1998) showed partial protection in 13 g rainbow trout immunized with a DNA vaccine encoding the nucleocapsid N gene of VHSV. In contrast, Anderson et al. (199613) reported no irnprovement in the survival rate of fish vaccinated with a pCMV-4-N DNA vaccine alone. However, they did show augmentation of the antibody response when the N DNA vaccine was included with the IHNV G DNA vaccine. These findings taken together led us to expect a better efficacy of the pCDNA-N vaccine used in our study. The lack of protection of fry immunized with our pCDNA-N vaccine confirmed the observation of Anderson et al. (1996b) and contrasts with the partial protection seen with the pCDNA-N vaccine of VHSV (Lorenzen et al. 1998) . The difference in fish size at the time of immunization may account for such contrasting results, or it may be that, unllke VHSV, IHNV N protein does not present the appropriate immunogenic epitopes to induce a protective immunity in trout. The absence of protection against vlral challenge in the groups of fish vaccinated wlth the pCDNA-N, pCDNA-P, pCDNA-M, and pCDNA-NV constructs, as well as the absence of neutralizing antibody titers, suggested that these proteins are poorly immunogenic to fish when formulated as DNA vaccines. However, due to the absence of confirmation of specific viral protein expression from the pCDNA-P, pCDNA-M, and pCDNA-NV constructs we cannot rule out the possibility that the lack of detectable immune response to these plasmids was due to lack of expression of the viral proteins Further tests are required to confirm the lack of irnmunogenicity of the internal proteins of IHNV.
Based on our first results, w e established a time course experiment that would shed some light on the duration of protection conferred by the pCDNA-G vaccine and would also confirm the lack of efficacy of 2 other constructs, pCDNA-N and pCDNA-NV, at inducing protection in fingerling rainbow trout. Results showed that up to 98% of the fish were protected at 28 d post-immunization. Significant protection was also conferred by the pCDNA-G vaccine at 58 and 80 d compared to the pCDNA-P-gal vaccine despite the intraperitoneal injection, a much more potent method of challenge necessary to overcome the natural immunity to IHNV that larger trout develop. In contrast, the N and NV vaccines did not show any improvement in protection at the 3 time points tested, demonstrating that longer 'incubation' periods did not improve the vaccines efficacy. In order to assess whether neutralizing antibody could be produced in immunized rainbow trout fry we analyzed sera at 80 and 102 d post-immunization. Among all groups, only 2 out of 11 trout vaccinated with the G vaccine had detectable IHNV neutralizing antibody titers. It is not clear why only a few fish responded; however, the genetic heterogeneity of outbred trout population used in our experiments may be a factor in this phenomenon. Neutralizing antibody titers were detected in all fry vaccinated with pCDNA-G that survived challenge against IHNV. In this case, it is most likely that the virus itself was responsible for the induction of neutralizing antibodies.
It has been shown that exposure of rainbow trout to live IHNV can induce neutralizing antibody titers ranging from 40 to 22560 . Our results showed that neutralizing antibody titers present in the sera of 150 g sockeye salmon immunized with pCDNA-G ranged from 80 to 320. The protection against IHNV provided by these sera to nai've fry suggests that neutralizing antibodies are involved in the protection of fish conferred by the pCDNA-G vaccine. However, in other studies the sera of salmonid fish immunized with the pCMV-4-G vaccine did not show detectable levels of neutralizing antibody and yet protected passively immunized nai've fry against IHNV challenge (unpubl. results). In addition, it has been shown that antibodies can be protective in fish (Lorenzen et al. 1990 ) or in mice (Corbeil e t al. 1996) without being able to neutralize viral particles in cell culture. We therefore cannot exclude the influence of other mechanisms in the protection observed in our passively immunized fry. The relatively low percent of mortality observed in fry passively immunized with the sera of sockeye salmon vaccinated with the pCDNA-P-gal negative control vaccine compared to the higher percent mortality observed in PBS and unhandled fish groups may be due to a nonspecific activity triggered either by the sockeye salmon serum itself or by the P-gal protein.
In summary, our results have clearly shown that, when expressed by a DNA vaccine construct, neither the internal structural proteins (N, P and M) nor the NV protein of IHNV induce protective immunity in fry and do not induce the production of neutralizing antibodies in large fish (unpubl. results). The G protein, however, does confer near to complete protection in fry and induces neutralizing antibodies in large fish a s well as in some rainbow trout fry. Upon passive transfer, these antibodies confer protection to naive fry against IHNV. To better understand the immune response of rainbow trout upon immunization with the pCDNA-G vaccine, w e are currently investigating non-antibody dependent mechanisms that may contribute to the protection conferred against IHNV.
